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Abstract
Atypical neuroleptics are increasingly used in the treat-
ment of bipolar and schizoaffective disorders. Currently,
numerous controlled short-term studies are available for
clozapine, olanzapine, risperidone or quetiapine, but
long-term data are still missing. Three patients (2 with
bipolar disorder, 1 with schizoaffective disorder) are de-
scribed who showed a marked reduction of affective
symptomatology after clozapine had been added to
mood stabilizer pretreatment. The patients were seen
once a month before and after the introduction of cloza-
pine for at least 6 months. Treatment response was eval-
uated using different rating scales (IDS, YMRS; GAF; CGI-
BP) and the NIMH Life Chart Methodology. All patients
showed a marked improvement after the add-on treat-
ment with clozapine had been initiated. Clozapine was
tolerated well with only transient and moderate weight
gain and fatigue as only side effects. This case series
underlines the safety and efficacy of clozapine as add-on
medication in the treatment of bipolar and schizoaffec-
tive disorders.
Copyright © 2002 S. Karger AG, Basel
Introduction
The management of bipolar and schizoaffective disor-
ders is a challenging task for clinicians. Although several
mood stabilizers, e.g., lithium, valproic acid or carbama-
zepine, are available, there is still a number of patients
unresponsive to either a monotherapy or even a combina-
tion treatment [1]. Lithium nonresponse is estimated at
33% in patients with ‘classical’ bipolar disorder [2] and
thought to be even higher in patients with mixed episodes
or rapid cycling [3, 4]. Additionally, manic patients are
still treated with typical antipsychotics in the acute phase
and even as maintenance treatment, despite the high risk
of tardive dyskinesia [5, 6]. A longitudinal study could
also demonstrate that the long-term use of neuroleptic
agents was associated with a cycle acceleration and thus a
worsening of the long-term course of the illness [7]. In
another double-blind study in which lithium monothera-
py was compared to the combination treatment of lithium
and flupentixol for 2 years, patients randomized to com-
bination treatment suffered from more depressive epi-
sodes while the frequency of manic episodes was not sig-
nificantly different [8]. Atypical antipsychotics such as
clozapine, olanzapine, risperidone or quetiapine are con-
sidered as relatively safe alternatives used as add-on med-
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ication in the maintenance treatment of bipolar and schi-
zoaffective disorders [9]. Hints at efficacy of clozapine in
schizoaffective [10–12] and bipolar disorders [13–15]
were reported by several authors. However, controlled
trials of clozapine in maintenance treatment are still miss-
ing. This might be not only due to the fact that clozapine
has the side effect of agranulocytosis, but also to a lack of
commercial interest in this relatively old drug.
Here we report on 3 well-characterized and followed-
up patients in whom clozapine as add-on medication led
to complete remission of symptoms.
Case Reports
Case 1
Mr. B. is a 34-year-old patient with bipolar I disorder and a rap-
id cycling course. His first depressive episode occurred at the age of
13, the first mania at the age of 15. Shortly after he developed a
rapid cycling course with mood switches every 14 days and without
any symptom-free interval. Combination treatment of lithium and
carbamazepine led to a complete remission of symptoms for 15
years. Then the ultrarapid cycling reoccurred, and additionally he
developed comorbid kleptomania, panic attacks, binge-eating disor-
der and marihuana abuse. Attempts to stabilize his mood with e.g.
valproate, lamotrigine or different antidepressants failed. He was
on a combination treatment with lithium, valproate, lamotrigine
and paroxetine without any change of his rapid cycling course when
he first visited our outpatient clinic. Both his depressive and manic
episodes ranged from moderate to severe. Especially in his de-
pressed phases, he had strong suicidal ideations. We decided to tap-
er lithium, lamotrigine and paroxetine gradually and to start treat-
ment with clozapine. After the titration phase, the daily dose of clo-
zapine was 250 mg. In the following 6 months, his manias subsided
completely, and the depressive episodes became fewer and milder.
With the later addition of ˆ-3 fatty acids it was possible to manage
also his depressive episodes. The combination treatment of val-
proate, clozapine and ˆ-3 fatty acids was shown to be safe and
effective. The only side effects were weight gain, fatigue and mild
diarrhea, which all subsided after some weeks of treatment. Con-
trolling his eating habits, the patient now even lost 14 kg of weight
and had no manias for 1 year and no severe depressions for several
months (fig. 1). Comorbid symptoms and suicidal ideations are no
longer present.
Case 2
Mr. R. is a 34-year-old patient with bipolar I disorder. His first
depressive episode with psychotic symptoms occurred at the age of
19. During the course of his illness, he had many very severe dys-
phoric manias, sometimes with mood-incongruent psychotic features
that always led to hospitalization and which were mostly treated with
the combination of lithium and carbamazepine as maintenance
treatment and haloperidol in the acute phase. During the 3 years
before he visited our outpatient clinic, he also received haloperidol as
a maintenance treatment. This led to an increase in the rate and
severity of the depressive episodes. We first put Mr. R. on the combi-
nation of lamotrigine and clozapine, but a severe manic episode in
which two hospitalizations were necessary led to the substitution of
lamotrigine with valproate. The daily dosage of clozapine is now
200 mg and that of valproate 1,500 mg. Mr. R. has been taking cloza-
pine in combination with valproate for 1 year now, and no recurrence
has been noted so far (fig. 2). Side effects are not present. Even with
the combination treatment of valproate and clozapine, Mr. R has lost
10 kg of weight since he stopped taking lithium, carbamazepine and
haloperidol as maintenance treatment. He is also able to exercise,
which he said he had not been able to do for years due to severe
fatigue.
Case 3
Ms. F. is a 23-year-old woman suffering from schizoaffective dis-
order. Besides her mood episodes, incongruent psychotic features
like paranoid delusions and ideas of reference were the prominent
symptoms, independently from mood deflections. Her first mania
occurred at the age of 20. At that time delusions were also prominent
symptoms. The treatment with risperidone 4 mg/day led to a fast
remission. After discontinuing the medication, she experienced
another exacerbation of mania which again led to hospitalization.
The treatment with valproate 1,500 mg/day led to a fast stabilization,
but still mild mood swings occurred. Shortly after her release, Ms. F.
had to be hospitalized again due to another manic episode. Besides
manic symptoms, psychotic symptoms were again prominent fea-
tures. In addition to valproate, haloperidol was necessary to treat the
psychotic symptoms. After the acute symptomatology had faded, we
tried to replace haloperidol with risperidone to continue with the
combination of valpraote and risperidone as maintenance treatment.
However, another exacerbation of the manic and psychotic symp-
toms occurred. A trial with olanzapine was also unsuccessful, due to
severe side effects (fatigue, depressive symptoms, difficulties to con-
centrate). We finally switched to a combination treatment of val-
proate 1,300 mg/day and clozapine 100 mg/day. During the titration
phase, Ms. F. suffered from fatigue; no other side effects occurred.
For the last 9 months, Ms. F. has had no more mood symptoms and
has tolerated the drugs without side effects (fig. 3).
Discussion
The 3 cases described here show that clozapine is a safe
and effective add-on medication in bipolar and schizoaf-
fective disorder. All patients tolerated it well. No blood
count changes have occurred yet. This case series is in line
with other reports and trials which describe clozapine as
an effective treatment for bipolar and schizoaffective
patients [9, 16]. In the 2 patients in whom also incon-
gruent psychotic features occurred, clozapine was an
effective antipsychotic as well. Keeping the risk of tardive
dyskinesia in mind and knowing that even nowadays
many bipolar patients still receive long-term treatment
with typical antipsychotics, clozapine seems to be an
alternative of choice. There is also the risk of inducing
depressive episodes by putting patients on typical antipsy-
chotics. Given that clozapine might not have strong anti-
depressant properties, it seems not to induce depression.
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In the cases described here, the only side effects which
occurred were fatigue and weight gain during the titration
phase. Later on, tolerability was no longer a problem.
Interestingly, 2 patients who suffered from severe weight
gain before they got clozapine and during the titration
phase even lost more than 10 kg during the continuation
treatment with the combination of clozapine and val-
proate. In summary, this case series is another hint at the
effectiveness and safety of clozapine in the treatment of
bipolar and schizoaffective disorders, but still more con-
trolled studies are necessary to further investigate the use
of clozapine and other atypical antipsychotics.
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